Jerusalem Pharmaceuticals (JPH) Stock Overview
Develops, manufactures, and markets pharmaceutical products in Palestine, the Middle East, North Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
JPH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Jerusalem Pharmaceuticals Co. Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.63 |
| 52 Week High | US$4.82 |
| 52 Week Low | US$3.55 |
| Beta | -0.017 |
| 1 Month Change | 0.65% |
| 3 Month Change | -1.49% |
| 1 Year Change | 22.49% |
| 3 Year Change | 19.33% |
| 5 Year Change | 67.15% |
| Change since IPO | 276.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| JPH | PS Pharmaceuticals | PS Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | -0.09% |
| 1Y | 22.5% | 21.6% | 22.1% |
Return vs Industry: JPH matched the PS Pharmaceuticals industry which returned 21.6% over the past year.
Return vs Market: JPH matched the PS Market which returned 22.1% over the past year.
Price Volatility
| JPH volatility | |
|---|---|
| JPH Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in PS Market | 6.9% |
| 10% least volatile stocks in PS Market | 2.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine JPH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 531 | Mohammed Mahmoud Masrouji | www.jepharm.ps |
Jerusalem Pharmaceuticals Co. Ltd., together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in Palestine, the Middle East, North Africa, and internationally. The company offers over the counter, prescription pharmaceutical, and nutritional supplements products in various dosage forms, including tablets, capsules, sterile injectables, powders for suspensions, suspensions, syrups, powders, suppositories, ovules, creams, and ointments, as well as ear and nose drops and solutions. It also provides medical devices; detergent; cosmetic; personal hygiene; veterinary; and agricultural products, as well as engages in printing services.
Jerusalem Pharmaceuticals Co. Ltd. Fundamentals Summary
| JPH fundamental statistics | |
|---|---|
| Market cap | US$83.34m |
| Earnings (TTM) | US$10.23m |
| Revenue (TTM) | US$49.93m |
Is JPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JPH income statement (TTM) | |
|---|---|
| Revenue | US$49.93m |
| Cost of Revenue | US$22.56m |
| Gross Profit | US$27.37m |
| Other Expenses | US$17.14m |
| Earnings | US$10.23m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.57 |
| Gross Margin | 54.81% |
| Net Profit Margin | 20.49% |
| Debt/Equity Ratio | 0.8% |
How did JPH perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/24 02:30 |
| End of Day Share Price | 2026/02/19 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jerusalem Pharmaceuticals Co. Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.